← Human Trials & Peer-Reviewed Studies
Anomalous growth hormone response to vasoactive intestinal peptide and peptide histidine methionine in patients with prolactinoma or hypothalamic hyperprolactinemia
Plain-language guide to PMID 7991068 (1994): randomized controlled trial study of VIP (Vasoactive Intestinal Peptide) in 22 patients, hyperparathyroidism.
Key Facts
- PMID
- 7991068
- Journal
- Neuropeptides
- Year
- 1994
- Study type
- Randomized Controlled Trial
- Authors
- Watanobe H et al. (3 authors)
- DOI
- 10.1016/0143-4179(94)90054-x
What This Study Did, in Plain Language
What Was Tested
Researchers studied VIP (Vasoactive Intestinal Peptide) in the context of hyperparathyroidism in this randomized controlled trial publication.
The researchers examined a possible GH-releasing activity of vasoactive intestinal peptide (VIP) and its homologous peptide, peptide histidine methionine (PHM), in 22 patients with hyperprolactinemia (HPRL) who comprised 19 cases of prolactinoma (PRLoma) and 3 cases of hypothalamic HPRL.
In agreement with previous reports, the PRL-releasing activity of VIP and PHM in their patients with HPRL were subnormal.
Who Took Part
The abstract describes 22 patients taking part.
By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got VIP (Vasoactive Intestinal Peptide) and who got the comparison, which limits bias.
What Was Measured
The researchers examined a possible GH-releasing activity of vasoactive intestinal peptide (VIP) and its homologous peptide, peptide histidine methionine (PHM), in 22 patients with hyperprolactinemia (HPRL) who comprised 19 cases of prolactinoma (PRLoma) and 3 cases of hypothalamic HPRL.
The subject headings attached to it are Growth Hormone, Hyperprolactinemia, Hypothalamic Diseases, Peptide PHI, Pituitary Neoplasms, Prolactinoma and Sequence Homology, Amino Acid.
What This Means in Plain Language
The paper is a randomized study of VIP (Vasoactive Intestinal Peptide) in 22 patients in people with hyperparathyroidism.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1994 (Neuropeptides), a journal based in Netherlands.
More context: the VIP (Vasoactive Intestinal Peptide) compound page, Hyperparathyroidism research.
Our Notes on the Compound
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.